These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 31986064)

  • 21. Progression-free survival and overall survival after BRCA1/2-associated epithelial ovarian cancer: A matched cohort study.
    Heemskerk-Gerritsen BAM; Hollestelle A; van Asperen CJ; van den Beek I; van Driel WJ; van Engelen K; Gómez Garcia EB; de Hullu JA; Koudijs MJ; Mourits MJE; Hooning MJ; Boere IA
    PLoS One; 2022; 17(9):e0275015. PubMed ID: 36137114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.
    Bednar EM; Oakley HD; Sun CC; Burke CC; Munsell MF; Westin SN; Lu KH
    Gynecol Oncol; 2017 Aug; 146(2):399-404. PubMed ID: 28610746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
    Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Japanese nationwide observational multicenter study of tumor BRCA1/2 variant testing in advanced ovarian cancer.
    Oda K; Aoki D; Tsuda H; Nishihara H; Aoyama H; Inomata H; Shimada M; Enomoto T
    Cancer Sci; 2023 Jan; 114(1):271-280. PubMed ID: 36254756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
    Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
    Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics.
    Kentwell M; Dow E; Antill Y; Wrede CD; McNally O; Higgs E; Hamilton A; Ananda S; Lindeman GJ; Scott CL
    Gynecol Oncol; 2017 Apr; 145(1):130-136. PubMed ID: 28162234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Germline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions.
    Lheureux S; Karakasis K; Harter P; Scott C; Bacon M; Bryce J; Le Fur N; Pujade-Lauraine E; Oza AM
    Gynecol Oncol; 2016 Jan; 140(1):90-4. PubMed ID: 26475959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Key messages for communicating information about BRCA1 and BRCA2 to women with breast or ovarian cancer: Consensus across health professionals and service users.
    Jacobs C; Pichert G; Harris J; Tucker K; Michie S
    Psychooncology; 2017 Nov; 26(11):1818-1824. PubMed ID: 28101941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic testing for epithelial ovarian cancer.
    Amin N; Chaabouni N; George A
    Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():125-138. PubMed ID: 32122773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Germline and somatic mutations of homologous recombination-associated genes in Japanese ovarian cancer patients.
    Sugino K; Tamura R; Nakaoka H; Yachida N; Yamaguchi M; Mori Y; Yamawaki K; Suda K; Ishiguro T; Adachi S; Isobe M; Yamaguchi M; Kashima K; Motoyama T; Inoue I; Yoshihara K; Enomoto T
    Sci Rep; 2019 Nov; 9(1):17808. PubMed ID: 31780705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.
    Weren RD; Mensenkamp AR; Simons M; Eijkelenboom A; Sie AS; Ouchene H; van Asseldonk M; Gomez-Garcia EB; Blok MJ; de Hullu JA; Nelen MR; Hoischen A; Bulten J; Tops BB; Hoogerbrugge N; Ligtenberg MJ
    Hum Mutat; 2017 Feb; 38(2):226-235. PubMed ID: 27767231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy.
    Schrader KA; Hurlburt J; Kalloger SE; Hansford S; Young S; Huntsman DG; Gilks CB; McAlpine JN
    Obstet Gynecol; 2012 Aug; 120(2 Pt 1):235-40. PubMed ID: 22776961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
    Le Page C; Rahimi K; Rodrigues M; Heinzelmann-Schwarz V; Recio N; Tommasi S; Bataillon G; Portelance L; Golmard L; Meunier L; Tonin PN; Gotlieb W; Yasmeen A; Ray-Coquard I; Labidi-Galy SI; Provencher D; Mes-Masson AM
    Gynecol Oncol; 2020 Feb; 156(2):377-386. PubMed ID: 31753525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
    Cotrim DP; Ribeiro ARG; Paixão D; de Queiroz Soares DC; Jbili R; Pandolfi NC; Cezana C; de Cássia Mauro C; Mantoan H; Bovolim G; de Brot L; Torrezan GT; Carraro DM; Baiocchi G; da Cruz Formiga MN; da Costa AABA
    BMC Cancer; 2019 Jan; 19(1):4. PubMed ID: 30606148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
    Alsop K; Fereday S; Meldrum C; deFazio A; Emmanuel C; George J; Dobrovic A; Birrer MJ; Webb PM; Stewart C; Friedlander M; Fox S; Bowtell D; Mitchell G
    J Clin Oncol; 2012 Jul; 30(21):2654-63. PubMed ID: 22711857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
    Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
    J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
    Haunschild CE; Tewari KS
    Gynecol Oncol; 2021 Jan; 160(1):333-345. PubMed ID: 33055011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of germline mutations in cancer-predisposing genes on long-term survival in patients with epithelial ovarian cancer.
    Kotsopoulos J; Zamani N; Rosen B; McLaughlin JR; Risch HA; Kim SJ; Sun P; Akbari MR; Narod SA
    Br J Cancer; 2022 Sep; 127(5):879-885. PubMed ID: 35710751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Universal BRCA1/BRCA2 Testing for Ovarian Cancer Patients is Welcomed, but with Care: How Women and Staff Contextualize Experiences of Expanded Access.
    Shipman H; Flynn S; MacDonald-Smith CF; Brenton J; Crawford R; Tischkowitz M; ; Hulbert-Williams NJ
    J Genet Couns; 2017 Dec; 26(6):1280-1291. PubMed ID: 28540621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
    Loman N; Johannsson O; Kristoffersson U; Olsson H; Borg A
    J Natl Cancer Inst; 2001 Aug; 93(16):1215-23. PubMed ID: 11504767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.